Answers are grounded in this paper and cite their sources.
Tumor-infiltrating B cells and tertiary lymphoid structures have been identified to predict the responses to immune checkpoint inhibitors (ICIs) in cancer immunotherapy. Considering the feasibility of sample collection, whether peripheral B cell signatures are associated with the responses to ICI therapy remains unclear. Herein, we have defined peripheral B cell signatures in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1 monotherapy and investigated their associations with clinical efficacy. It was found that the percentages of B cells before the treatment (baseline) were significantly higher ( P = 0.004) in responder (R, n = 17) than those in non-responder (NonR, n = 33) NSCLC patients in a discovery cohort. Moreover, the percentages of baseline IgM + memory B cells were higher ( P < 0.001) in R group than those in NonR group, and associated with a longer progression free survival (PFS) ( P = 0.003). By logistic regression analysis peripheral baseline IgM + memory B cells were identified as an independent prognostic factor ( P = 0.002) for the prediction of the responses to anti-PD-1 monotherapy with the AUC value of 0.791, which was further validated in another anti-PD-1 monotherapy cohort ( P = 0.011, n = 70) whereas no significance was observed in patients receiving anti-PD-L1 monotherapy ( P = 0.135, n = 30). Therefore, our data suggest the roles of peripheral IgM + memory B cells in predicting the responses to anti-PD-1 treatment in Chinese advanced NSCLC patients.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: